



Recursion.

(L)earnings 1Q25

May 2025

Important Information

This presentation of Recursion Pharmaceuticals, Inc. ("Recursion," "we," "us," or "our") and any accompanying discussion contain statements that are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "potential," "predicts," "projects," "seeks," "should," "will," or words of similar meaning and include, but are not limited to, statements regarding Recursion's ability to demonstrate the potential of technology-driven approaches to increase speed, quality and the scalability of drug discovery; the potential outlook for programs being prioritized and deprioritized; Recursion's future as a leader in TechBio and ability to deliver better treatments to patients faster; Recursion's OS industrializing first- and best-in-class drug discovery; the occurrence or realization of potential milestones; current and future preclinical and clinical studies, including timelines for enrollment in studies, data readouts, and progression toward IND-enabling and other potential studies; advancements of its pipeline, partnerships, and data strategies; the potential size of the market opportunity for our drug candidates; outcomes and benefits from licenses, partnerships and collaborations, including option exercises by partners and the amount and timing of potential milestone payments; the initiation, timing, progress, results, and cost of our research and development programs; advancements of our Recursion OS; the potential for additional partnerships; our ability to identify viable new drug candidates for clinical development and the accelerating rate at which we expect to identify such candidates including our ability to leverage the datasets acquired through the license agreement into increased machine learning capabilities and accelerate clinical trial enrollment; Recursion's cash position and cash runway; the completion of core integration plans and the results of the business combination with Exscientia; and many others.

Other important factors and information are contained in Recursion's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and the Company's other filings with the U.S. Securities and Exchange Commission (the "SEC"), which can be accessed at <https://ir.recursion.com>, or www.sec.gov. All forward-looking statements are qualified by these cautionary statements and apply only as of the date they are made. Recursion does not undertake any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.


Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company's own internal estimates and research. While the company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source. Information contained in, or that can be accessed through our website is not a part of and is not incorporated into this presentation.

Cross-trial or cross-candidate comparisons against other clinical trials and other drug candidates are not based on head-to-head studies and are presented for informational purposes; comparisons are based on publicly available information for other clinical trials and other drug candidates.

Any non-Recursion logos or trademarks included herein are the property of the owners thereof and are used for reference purposes only.


Recursion's Mission: Decode Biology to Radically Improve Lives

Biotech




vs.

Recursion





Recursion OS delivers a decisive, data-led portfolio strategy




Evolution of our platform reflects the evolution of our portfolio




Evolution of our platform reflects the evolution of our portfolio



Evolution of our platform reflects the evolution of our portfolio



Recursion OS moves medicines to clinic faster and at a lower cost



(Far Left): Time from hypothesis screening to validated hit package for legacy Recursion programs. (Center Left): Legacy Exscientia compounds synthesized from hit to candidate ID. (Center Right): Total spend from hypothesis screening to the completion of IND-enabling studies for legacy Recursion novel chemical entity (NCE) programs that advanced to clinical trials. The cost to IND has been inflation-adjusted using the US Consumer Price Index (CPI) (Far Right). Time to validated lead is the average of >280 legacy Recursion programs since late 2017 through 2024. Industry data adapted from Paul, et al., Nature Reviews Drug Discovery (2010) 9, 203-214

Sharpening our focus: Why Now



Commit to streamlined integrated portfolio

Deliver on our commitment to a streamlined post-integration pipeline and overall operations by 1Q25, enabling a disciplined R&D strategy built for near and long-term impact



Prioritize with integrated Recursion OS 2.0 platform

Rapidly validate emerging opportunities, double down on winners, and decisively exit efforts that do not meet our bar



Continue to invest in transformational value creation

Focused go-forward strategy, allows for targeted investment in platform and high impact programs, and to fuel innovation with financial discipline amid an uncertain macro environment

Go-Forward Pipeline: Advancing 5+ High-Potential Programs Across Oncology & Rare Disease


	Candidate	Target	BIC/FIC	Indication	Preclinical	IND-Enabling	Phase 1 / 2	Phase 3
ONCOLOGY	REC-617	CDK7	BIC	Advanced solid tumors ¹	<i>ELUCIDATE</i>			
	REC-1245	RBM39	FIC	Biomarker-enriched solid tumors & lymphoma	<i>DAHLIA</i>			
	REC-3565	MALT1	BIC	B-cell malignancies	<i>EXCELERIZE</i>			
	REC-7735	PI3Kα H1047R	BIC	Breast Cancer				
RARE	REC-4881	MEK1/2	FIC	Familial adenomatous polyposis (FAP)	<i>TUPELO</i>			
	REV102 ²	ENPP1	FIC	Hypophosphatasia (HPP)				
	REC-4539 – strategic pause ³	LSD1	BIC	Solid tumors (e.g., SCLC)	<i>ENLYGHT</i>			

3 clinical programs deprioritized: REC-994 for CCM, REC-2282 for NF2, REC-3964 for prevention of recurrent *C. difficile* infection

1 preclinical program (REC-4209 for IPF) has also been deprioritized as part of a disciplined, strategic portfolio prioritization, following the integration

1. Includes non-small cell lung cancer (NSCLC), colorectal cancer, breast cancer, pancreatic cancer, ovarian cancer, head and neck cancer
2. Joint Venture with Rallybio
3. Strategic pause to ensure a competitive Target Product Profile

Pharma partnerships with approximately \$455M¹ earned to date and potential to receive more than \$20B in additional milestones



Portfolio Update

Go-Forward Pipeline: Advancing 5+ High-Potential Programs Across Oncology & Rare Disease


	Candidate	Target	BIC/FIC	Indication	Preclinical	IND-Enabling	Phase 1 / 2	Phase 3
ONCOLOGY	REC-617	CDK7	BIC	Advanced solid tumors ¹	<i>ELUCIDATE</i>			
	REC-1245	RBM39	FIC	Biomarker-enriched solid tumors & lymphoma	<i>DAHLIA</i>			
	REC-3565	MALT1	BIC	B-cell malignancies	<i>EXCELERIZE</i>			
	REC-7735	PI3Kα H1047R	BIC	Breast Cancer				
RARE	REC-4881	MEK1/2	FIC	Familial adenomatous polyposis (FAP)	<i>TUPELO</i>			
	REV102 ²	ENPP1	FIC	Hypophosphatasia (HPP)				
	REC-4539 – strategic pause ³	LSD1	BIC	Solid tumors (e.g., SCLC)	<i>ENLYGHT</i>			

3 clinical programs deprioritized: REC-994 for CCM, REC-2282 for NF2, REC-3964 for prevention of recurrent *C. difficile* infection

1 preclinical program (REC-4209 for IPF) has also been deprioritized as part of a disciplined, strategic portfolio prioritization, following the integration

1. Includes non-small cell lung cancer (NSCLC), colorectal cancer, breast cancer, pancreatic cancer, ovarian cancer, head and neck cancer
2. Joint Venture with Rallybio
3. Strategic pause to ensure a competitive Target Product Profile

Sharpening our focus: Go-forward programs powered by Recursion OS



Note: Addressable patient populations estimate based on annual US+EU5 and currently identified indications

1. Includes ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, pancreatic cancer, head and neck cancer
2. Biomarker-enriched
3. Joint Venture with Rallybio
4. Diagnosed patients

Sharpening our focus: Disciplined deprioritization – focus where we can win

REC-2282 NF2	<ul style="list-style-type: none">• New findings:<ul style="list-style-type: none">• Phase 2 for NF2-related meningioma passed the futility threshold, primarily driven by the 40 mg cohort; however, the 60 mg and combined dose arms did not pass the futility criteria• Limited tumor shrinkage and clinical activity across all arms• Totality of data supports the discontinuation of study
REC-994 CCM	<ul style="list-style-type: none">• Early data suggested potential promising trends in exploratory efficacy endpoints at 400mg (mean volume reduction, mRS), negative trends in efficacy at 200mg (data were not statistically significant)• New findings: Long-term extension results showed no promising trends in MRI or functional outcomes in the placebo-to-400mg crossover, and the 400mg-to-400mg arm did not continue prior trends and was indistinguishable from natural history• Totality of data supports the discontinuation of study
REC-3964 <i>C. difficile</i>	<ul style="list-style-type: none">• Evolved treatment options result in lower recurrence rates (~5%); thus limiting unmet need• Strategic decision to focus on areas with greater unmet need• Will consider out license opportunities

Targeted, Differentiated Go-Forward Portfolio Strategy

Powered by the Recursion OS 2.0 platform

Differentiated, product first mindset, powered by Recursion OS 2.0

Integrated, end-to-end tech stack

Multimodal Biology · Design · ClinTech

Explore the uncharted by going after **novel targets** to develop differentiated medicines

First-in-class molecules

Provide **significantly meaningful advancements** with differentiated medicines

Best-in-class molecules


Double down on areas of **expertise and efficiency**

Oncology · I&I · Neuroscience · Rare

Develop **innovative molecules in-house, powered by our platform**




Focus on **quick and clear go/no-go, differentiated TPP that enable rapid POC**

Internal pipeline momentum: Near Term Catalysts Through 2025 and 2026



Rare Disease

MEK 1/2



REC-4881: Allosteric MEK1/2 Inhibitor

A highly selective, potent MEK1/2 inhibitor as chemoprevention for Familial Adenomatous Polyposis (FAP)

Unmet need¹

- **No systemic therapies** for ~50,000 FAP patients beyond colectomy
- **~15,000 patients** post colectomy, >55 years old

Mechanism of Action

- **Potent, non-competitive, allosteric** MEK1/2 inhibitor

Thesis & Differentiation

- **First oral therapy**, targeting underlying genetic mechanisms
- **Preferential distribution to GI tissues** -> greater activity at lower doses


Recursion Approach

- **Unbiased ML-aided phenotypic** drug screen in **human cancer cells**
- **Validated findings** in vivo demonstrating significant reductions in polyps and adenomas

Program Status

- **Enrollment ongoing**; additional efficacy and safety data, **2H25**

Platform Insight: The AI-powered Recursion OS was leveraged to uncover novel therapeutic mechanisms relevant for FAP




REC-4881 Discovery

- The platform analyzed cellular models of APC gene loss—the root cause of FAP
- **AI/ML** extracts morphological features to **distinguish “diseased”** vs. **“healthy”** states
- Numerous compounds screened to identify therapeutic mechanisms that **reverse disease state back to healthy** in a concentration-dependent manner
- **REC-4881** (an **allosteric MEK 1/2 inhibitor**) demonstrated **potent** and **concentration dependent rescue**

Phase 1b and Phase 2: REC-4881-201 study design & objectives

- Two stage study designed to assess safety, tolerability, PK/PD and **preliminary efficacy of REC-4881 in FAP**
- Phase 1b (safety run-in) followed by Phase 2 (open-label) evaluating once-daily **REC-4881 for 12 weeks**

Phase 1b

 **Completed:**

Single and Multiple Dose Safety

Randomized, double-blind, placebo-controlled (N=7)

5 patients dosed 4 mg,
2 on placebo


Study Objectives:

Safety/tolerability
Pharmacokinetics
Pharmacodynamics

Key Eligibility: FAP \geq 18 years old

Phase 1b and Phase 2: REC-4881-201 study design & objectives

- Two stage study designed to assess safety, tolerability, PK/PD and **preliminary efficacy of REC-4881 in FAP**
- Phase 1b (safety run-in) followed by Phase 2 (open-label) evaluating once-daily **REC-4881 for 12 weeks**



1. Efficacy Evaluable Population: Defined as all participants who have measurable disease (non-zero polyp burden) at end of baseline endoscopy, received at least 75% of study drug, and have at least one post-baseline on study endoscopic assessment
2. After analysis in Phase 1b the eligibility criteria was shifted to enroll only patients 55+ years of age to minimize TRAEs associated with MEK1/2 inhibition
3. Participants from RP2D in Dose Finding will Contribute to the sample size in Cohort Expansion

Phase 1b and Phase 2: REC-4881 summary of adverse events

Event, n (%)	Placebo (N=2)	REC-4881 4 mg (N=16) ³	REC-4881 8 mg (N=3)	REC-4881 Total (N=19)
Any Treatment Emergent Adverse Event (TEAE)	2 (100)	13 (81.2)	3 (100)	16 (84.2)
TEAEs Grade ≥3	0	5 (31.2)	0	5 (26.3)
Any TEAE related to study drug (TRAE)	1 (50.0)	13 (81.2)	2 (66.7)	15 (78.9)
Grade ≥3 TRAE	0	3 (18.8)	0	3 (15.8)
Discontinuation due to Related-TEAE	0	3 (18.8)	0	3 (15.8)
Dose interruption due to Related-TEAE	0	1 (6.20)	0	1 (5.3)
Dose modification due to Related-TEAE	NA	0 ²	1 (33.3)	1 (5.3)

REC-4881 Preliminary Safety


4 mg dose:

- **Most common TRAEs:** dermatitis acneiform (50%; All G1/2), rash (31.2%; 25% G1/2 and 6% G3), diarrhea (31.2%; All G1/2), blood CPK increase (25%; All G1/2), and LVEF decrease (25%; 19% G1/2, 6% G3)
- **Grade 3 TRAEs:** Rash (6%, n=1), CRP increase (6%, n=1), LVEF Decrease (6%, n=1)¹

8 mg dose:

- **No Grade 3 TRAEs**
- **Grade 2 TRAEs:** Rash (33%, n=1)

Preliminary Results: 43% median reduction in total polyp burden on 4 mg REC-4881



Data excludes one 4mg patient who received only 3 weeks of REC-4881 dosing and WK13 endoscopy was performed 10 weeks post last dose. Percent (%) change from baseline calculates the change between post-resection value from screening visit to the pre-resection value at Week 13/EOT visit. Subjects with absolute value of 0 at baseline are not displayed.


Data Snapshot Date: 2025-04-02; Data Cut-off Date: 2025-03-17; Report generated on: 2025-04-28

REC-4881 Preliminary Efficacy

- **6 patients** on 4 mg efficacy evaluable¹
 - 100% (n=6) on therapy for at least 9 weeks
- **43% median reduction** in total polyp burden
- **> 30% reduction** in total polyp burden (sum of polyp diameters) at week 13 assessment
- **At week 25, 2 out of 2 patients** on the 12-week on/12-week off regimen **maintained a durable >30% reduction**²

Preliminary Results: Reductions in polyp burden seen across upper and lower GI tract

Waterfall Plot of % Change from Baseline in Upper or Lower Polyp Burden at Week 13/EOT



REC-4881 Preliminary Efficacy

• Upper GI Burden

- **6 patients** efficacy evaluable¹
- **58% median reduction** in UGI polyp burden

• Lower GI Burden

- **5 patients** efficacy evaluable¹
- **57% median reduction** in LGI polyp burden

Data excludes one 4mg patient who received only 3 weeks of REC-4881 dosing and WK13 endoscopy was performed 10 weeks post last dose. Percent (%) change from baseline calculates the change between post-resection value from screening visit to the pre-resection value at Week 13/EOT visit. Subjects with absolute value of 0 at baseline are not displayed. Data Snapshot Date: 2025-04-02; Data Cut-off Date: 2025-03-17; Report generated on: 2025-04-28

Preliminary Results: 50% of patients on 4 mg REC-4881 demonstrated a reduction in Spigelman stage

Subject ID	Polyp Burden Screening -> W13 (CfB%)	Polyp Count Screening -> W13 (CfB%)	Spigelman Stage Screening ->W13
001-2001	-31%	-22%	NA-> II
016-2001	-50%	-56%	III -> I
016-2002	-69%	-78%	IV -> II
003-2001	-82%	-79%	III -> II
003-2002	-37%	-35%	II -> II
001-2003	+595%	+454%	II -> IV

>20% decrease (PR)	±20% increase/decrease (SD)	>20% increase (PD)
--------------------	-----------------------------	--------------------

*Spigelman Stage can be confounded by sampling errors

REC-4881 Preliminary Efficacy

- **Two patients** with a 2-point change in Spigelman Stage
- **Effects in upper GI include** polyp burden reduction, polyp count, and Spigelman downstaging

REC-4881: MEK1/2 – Summary and Next Steps



Biological Insight

MEK1/2 inhibition identified as a unique mechanism for FAP through an unbiased ML-aided phenotypic screen



In Vivo Data

Significant reduction in **both polyp count** and **precancerous adenomas** at lowest dose tested



Clinical

43% median reduction in total polyp burden at week 13 and **50%** of patients demonstrated **reduction in Spiegelman Stage**

REC-4881 Target Profile




- **Orally bioavailable**, highly potent and selective MEK1/2 inhibitor
- **Differentiated ADME** profile may enhance exposures at the site of GI adenomas
- 4mg dose **well-tolerated** with a safety profile consistent with MEK inhibitors
- **ODD** in US and EU; **FTD** in US

What's Next

- **Enrollment ongoing**; additional efficacy and safety data, **2H25**

Oncology

PI3K α H1047R



REC-7735: PI3K α H1047R

A precision designed highly selective for PI3K α H1047R for PI3K mutant-selective cancers

Unmet need

- **14%¹ of all HR+/HER2- Breast cancer** with PI3K α -H1047R mutation
- **~11,000²** advanced or metastatic patients

Mechanism of Action

- **PI3K α -H1047R mutant selective inhibitor**

Thesis & Differentiation³

- **CNS penetrant** molecule, **>100x selectivity** vs WT PI3K α
- **Low risk** of AEs
- **Superior in vivo efficacy vs Alpelisib & Capivasertib**, comparable to STX-478
- **Synergy with SERD \pm CDK4/6i** combo at **low doses**

Recursion Approach

- AI-powered precision design to **optimize selectivity** and **limit** metabolic liabilities such as **hyperglycemia**
- 242 novel compounds synthesized to candidate ID

Program Status


- Candidate Profiling
- **DC nomination 2H25**

1. Mutation prevalence: [Millis et al. \(2016\)](#); [Martinez-Saez et al. \(2020\)](#)



2. First Line treated incidence for HR+ HER2- BC in US and EU5 from 2024 EvaluatePharma Epi multiplied by mutation prevalence

3. Based on preclinical data

Platform Insight: Recursion OS leveraged to maximize selectivity, developing a structurally differentiated molecule with superior ADME



Demonstrated preliminary competitive efficacy with no hyperglycemia versus SoC in preclinical models




Note: Alpelisib and STX (STX-478) were dosed QD; LOXO (LOXO-783) and REC-7735 were dosed BID. Doses are represented as mg/kg. LOXO has been discontinued

- In vivo CDX Model using T47D (PI3Ka H1047R mutant) cell line. n=10 mice per group. Data represents tumor growth inhibition and regression after 14 days of dosing. Pharmacokinetic (plasma and tumor) and pharmacodynamic (tumor pAKT) data were consistent with the observed tumor growth inhibition and regression.
- In vivo naïve wild-type, non-tumor bearing mice. n=6 mice per group. Data represents plasma insulin after 5 days of dosing. To note, plasma glucose and serum C-peptide, an inflammation marker, showed similar trends.

Low dose outperforms high dose SoC Capiivasertib (AKTi)¹

CDX Model: PI3Ka H1047R²




- REC-7735 (6.25mg/kg BID) shows similar anti-tumor activity to Capiivasertib (100mg/kg BID)
 - AKT inhibitor, shown promising clinical efficacy with endocrine therapy
- **REC-7735 (18.75mg/kg BID) significantly outperforms high-dose Capiivasertib (100mg/kg BID)**
- Capiivasertib caused significant body weight loss and animal deaths, while **REC-7735 was well-tolerated**

1. Capiivasertib (AKTi) in combination with fulvestrant (SERD) is used in breast cancer (HR+/HER2-) for patients with PIK3CA, AKT1, or PTEN alteration in combination with fulvestrant (SERD).

2. In vivo CDX Model using T47D (PI3Ka H1047R mutant) cell line. n=8 mice per group. Data represents tumor growth inhibition and regression after 21 days of dosing.

Low dose outperforms & synergizes SoC Fulvestrant (SERD) ± Abemaciclib (CDK4/6i) combo¹

CDX Model: PI3Ka H1047R²



- REC-7735 shows strong, significant tumor regression at low doses (≥ 6.25 mg/kg BID)
- REC-7735 alone outperforms Fulvestrant/Abemaciclib combination therapy
- Even low-dose REC-7735 significantly enhances the efficacy of Fulvestrant ± Abemaciclib

1. Fulvestrant (SERD) alone and or in combination with Abemaciclib (CDK4/6i) is used in HR+/HER2- advanced or metastatic breast cancer.


2. In vivo CDX Model using T47D (PI3Ka H1047R mutant) cell line. n=8 mice per group. Data represents tumor growth inhibition and regression after 14 days of dosing.

REC-7735: PI3K α H1047R – Summary & Next Steps



Biological Insight

High selectivity for **H1047R mutant PI3K α** over WT to reduce dose-limiting hyperglycemia



Design

AI-driven generative design via **hotspot molecular dynamics** to discover a **unique chemical series**



In Vivo Data

Significant tumor regressions at low doses **outperforms** clinically approved agents



Clinical

Data supports targeting **H1047R mutant breast cancer** as a **monotherapy** or in **combination** with standard of care treatments




REC-7735 Target Profile

- Potential **best-in-class** PI3K α H1047R inhibitor
- **>100-fold selective** against WT PI3K α
- **No significant** in-vitro safety concerns, superior BSEP, off-target & liver spheroid profile **versus competitors**
- **Highly CNS penetrant** with **low-risk** of dose-limiting AEs

What's Next

- Development candidate nomination **2H25**

Rare Disease
ENPP1



REV102: ENPP1 Inhibitor

A preliminarily non-immunogenic, potent, highly selective ENPP1 inhibitor for hypophosphatasia (HPP) in development with Rallybio

Unmet need¹

- **~7,800 diagnosed** HPP patients, mostly with limited ERT access
- Opportunity to **significantly reduce costs**

Mechanism of Action

- **Potent, highly selective ENPP1** inhibitor

Thesis & Differentiation

- **First oral disease-modifying therapy**
- **ENPP1** inhibition a **genetically validated** target in HPP models
- **Non-immunogenic** small molecule, potentially safer than ERT
- **More tolerable and affordable** vs ERTs

Recursion Approach²

- **Precision designed for both high potency, chronic dosing**
- **Maintained selectivity** for candidate with **high oral bioavailability** in clinic

Program Status

- **IND-enabling studies ongoing**
- **Phase 1 initiation expected 2H26**

Note: ERT = Enzyme Replacement Therapy

1. HPP prevalence at birth across US+EU5. Mornet et al, 2020

2. Joint Venture with Rallybio

Platform Insight: Precision designed for both high potency and a lifetime of chronic dosing using Recursion OS

Biology

Novel insights

- **ENPP1 inhibition** helps correct phenotypes caused by **LOF mutations in ALPL gene**
- **Oral drug** reduces cost and improves convenience and access over ERT



Generative Approach



ML models



Selection Coverage Score

Design

Novel scaffolds


- Structurally distinct molecules to prevent selectivity issues

High bar for safety

- Optimized pharmacophore against closely-related metalloenzymes through structural enablement and 3D / ML model platform

Low (predicted) human oral dose

- Highly optimized ADME using robust 2D ML methods




3D interaction filters

Prioritize

Efficient unbiased testing

- Modern use of information theory to select fewest compounds for testing but with maximal information gain




Recursion OS Platform:



A highly potent, selective, orally bioavailable compound developed through our multi-parameter optimization engine

Preclinical: REV102 restores bone health and survival in an unpublished *ALPL* early-onset knockout mouse model of HPP

In Vivo Efficacy



- REV102 **extends survival** in an early-onset *ALPL* KO mice model
- REV102 **transiently reduces PPI levels** to enhance mineralization
- **Tibia BMD is fully restored to wildtype** levels in treated mice




1. N=10 mice in wildtype group, N=5 mice in ALPL KO group, N=7 in Strensiq and REV102 groups. REV102 and Strensiq administered QD SC. Vehicle treated ALPL KO mice stopped growing at day 7-10 and all died at day 22
 2. PPI concentrations at 2h or 24h after the last dose of 30 mg/kg REV102. <LLOQ data points are shown on the graph as 0 values.
 3. ALPL KO group not shown given all mice die around weaning age

Preclinical: Chronic dosing of REV102 improves bone phenotype in a late-onset knockout mouse model of HPP

In Vivo Efficacy¹

Late-Onset HPP Model²



Wildtype

Control KO

REV102 30mpk

REV102 100mpk


Patella (yellow arrow)

Growth plate (green arrow)

- Untreated mice present **underdeveloped patellofemoral** joints
- REV102 treatment corrects bone defect and **improves patella structure**
- REV102 treatment **significantly reduces plasma PPI concentrations**



Plasma PPI




REV102: ENPP1 – Next Steps



Biological Insight

Reduction of PPI production via controlled ENPP1 inhibition to restore bone hypomineralization



Design

AI-driven generative design via **fragment screening** to enhance **metalloenzyme selectivity**



In Vivo Data

Significant survival benefit in HPP mice through transient PPI reduction validates mechanistic rationale



Clinical

Opportunity to address significant unmet needs in **juvenile** and **adult-onset HPP patients**

REV102 Target Profile

- Potential **first-in-class** ENPP1 inhibitor
- **High oral bioavailability** supports QD or BID dosing
- **No kinases** inhibited >70% at 10 μ M
- No significant in-vitro safety liabilities identified




What's Next

- IND-enabling studies **ongoing**
- **Phase 1 initiation 2H26**

Clinical Portfolio

Oncology


RBM39 · CDK7 · MALT1



REC-1245 (RBM39 degrader): Summary & next steps

Monotherapy dose escalation ongoing with preliminary update 1H26


Recursion OS Insight



Identified through phenotypic discovery platform

- Novel target mimicking CDK12 loss
- Hypothesized to modulate DDR


Preclinical Validation



Compelling efficacy and PK/PD with REC-1245 treatment

- REC-1245 shows significant monotherapy regressions
- Dose-dependent antitumor activity correlates with PD

Clinical Development



Ongoing ClinTech work to accelerate enrollment and identify new indications

- Using RWD to identify quality sites for faster enrollment
- Ongoing causal AI modeling to explore potential additional indications

REC-617 (CDK inhibitor): Summary & next steps

Monotherapy dose escalation ongoing with update 1H26; Combination study to initiate 1H25

Recursion OS Insight

Preclinical Validation

Clinical Development


Target affinity and selectivity	CDKC IC ₅₀ (nM)	
	CDK family selectivity	
Cell potency	HCC70 (breast cancer) IC ₅₀ (nM)	
	OVCAR-3 (ovarian cancer) IC ₅₀ (nM)	
Safety and metabolism	hERG IC ₅₀ (μM)	
	Human microsome Clint μL/min/mg	
	Human hep Clint μL/min/10 ⁶ cells	
ADME	Caco-2 A2B (efflux) 10 ⁶ cm/s	
	pH 7.4 μg/mL	
	F % (p.o.)	

136 novel compounds
to Candidate ID in **<12 months**

Designed to optimize PK/PD and maximize potential therapeutic index

- 2D ML to optimize ADME for high permeability and low efflux
- 3D ML maximized key pocket interactions & selectivity against related kinases


CDX Model: OVCAR¹



Potent tumor regression with REC-617 treatment

- <10 hours of exposure above IC₈₀ to optimize benefit-risk
- No body weight loss

CDK7 Expression and Overall Survival



Human Genetics Data and Cell Line screens to validate new indications

- Causal AI approach to determine impact of CDK7 inhibition on survival
- 2 new potential indications identified

1. Besnard et al, AACR (2022)

2. By RECIST 1.1. Response evaluation criteria in solid tumors, PR: decrease of more than 30% in the sum of the longest diameters of target lesions + no new lesions + no progression of non target lesions.


REC-3565 (MALT1 inhibitor): Summary & next steps

Monotherapy dose escalation ongoing with preliminary update 1H26

Recursion OS Insight

Preclinical Validation

Clinical Development




344 novel compounds
to Candidate ID

Designed to deliver balanced compound with improved safety (UGT1A1) and efficacy

- Leveraged molecular dynamics & hotspot analysis

CDX Model: OCI-Ly10¹



Single-agent and synergistic activity

- Single agent showed tumor growth regression
- 70% of mice in combo arm had no palpable tumors 10-days after last dose

Illustrative example






RWD to combat competition for trial enrollment

- Advanced analytics for strategic site recommendations and patient targeting
- >50 new potential sites identified in UK and Spain


Portfolio

Partnered Programs



Sanofi collaboration advancing novel targets in I&I and oncology

- 4 milestones achieved, multiple additional expected



4 Program milestones achieved to date

What's next

- **Complete first development candidates** and advance programs into the clinic
- Continue to **advance broad pipeline** of first-in-class and best-in-class medicines with Recursion OS

Roche and Genentech collaboration within Neuroscience and GI Oncology Indication – unbiased novel biological insights to programs

Biology

Design


Optimize

~5 Phenomaps


Derived from over
**1 Trillion iPSC cells and
100 Billion GI Onc relevant cells**

~5,000 transcriptomes

From multiple disease-relevant cell types,
subjected to **compound treatments and/or
gene KO**, resulting in **~ 171 TB of data**



Lab in the Loop



Collaboratively working to identify novel biological insights from phenomaps for validation

What's next

- **Additional phenomap** builds ongoing
- Leveraging Recursion OS and collaborating with Roche and Genentech to **identify new programs** in a GI Oncology Indication & Neuroscience

Recursion OS Platform

Internal and External Pipeline Momentum

FY 2025 and 2026 Upcoming Pipeline Catalysts

H1

REC-617 (CDK7i) in advanced solid tumors
Initiation of combination studies

H2

REC-4881 (MEK1/2i) in FAP
Additional safety and efficacy data from TUPELO

REC-617 (CDK7i) in advanced solid tumors
Additional Phase 1 data from ELUCIDATE

REC-7735 (PI3K α H1047Ri)
DC nomination

H1

REC-1245 (RBM39)
Early safety and PK from monotherapy trial

H2

REC-3565 (MALT1)
Early safety and PK from monotherapy trial

REV102 (ENPP1i)
Ph1 initiation – 2H26

2025

2026

Partnership Catalysts

Potential for **additional phenomap options**

Potential for **multiple new project initiations**

Potential for **multiple programs optioned** by partners



Merck KGaA
Darmstadt, Germany

sanofi



Financial Update

Focusing resources on core capabilities to improve probability of success in the industry

- Prioritized pipeline and streamlined operations
- Reduced platform costs associated with capacity, while protecting capability
- Continued investment in key aspects of platform to drive near and long-term value
- Delivering on partnerships and continue to achieve cash-generating milestones
- Limited expected impact to business from macro factors (China & tariffs)

\$509.2 million in cash¹ as of March 31, 2025

1Q25 cash burn² of \$118 million, excluding:

- Partnership inflows
- Financing inflows
- Transaction costs

Expected cash runway until mid-2027

On track to achieve substantial cost savings as a combined entity

FY2024

\$606 million

combined cash burn, excluding partnership and financing inflows:

Cash flow items ¹	2024 (\$m)
RXRX cash flow from operating activities	(359)
RXRX capital expenditures	(14)
RXRX partnership inflow addback	(30)
EXAI pre-combination net cash flows	(184)
EXAI partnership inflow addback	(19)
Total combined	\$(606)

FY2025E

≤\$450 million

expected cash burn, excluding potential partnership and financing inflows:

Primary areas of budget savings:

- Pipeline prioritization
- Duplicated corporate expenses
- Reduction in capacity of platform
- Increasing administrative efficiency
- Rationalization of facilities and office locations
- Greater purchasing power with vendors
- Carve out of Austrian operations

Recursion 2.0

Solidifying Recursion's leadership in TechBio

Our sustainable and continued growth plan

- **Commitment to internal pipeline** – Strong investment behind more focused pipeline
- **Execution on partnerships** – Fully resourced to deliver on programs and achieve milestones
- **Transforming drug discovery and development** – Expanding leadership in AI-based drug discovery and automation by advancing differentiated molecules
- **Increasing efficiency** – Our scale and technologies continue to allow us to do more with less
- **Investment in Recursion OS** – Integrated end-to-end tech stack driving better decision making



Q&A